Trinity Biotech PLC (TRIB)
1.69
0.00 (0.00%)
USD |
NASDAQ |
Nov 04, 16:00
1.69
0.00 (0.00%)
After-Hours: 16:51
Trinity Biotech Research and Development Expense (Annual): 4.379M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.379M |
| December 31, 2022 | 4.138M |
| December 31, 2021 | 4.497M |
| December 31, 2020 | 5.08M |
| December 31, 2019 | 5.325M |
| December 31, 2018 | 5.369M |
| December 31, 2017 | 5.657M |
| December 31, 2016 | 5.04M |
| December 31, 2015 | 5.069M |
| December 31, 2014 | 4.291M |
| December 31, 2013 | 3.691M |
| December 31, 2012 | 3.13M |
| December 31, 2011 | 3.206M |
| December 31, 2010 | 4.603M |
| Date | Value |
|---|---|
| December 31, 2009 | 7.341M |
| December 31, 2008 | 7.544M |
| December 31, 2007 | 13.71M |
| December 31, 2006 | 6.696M |
| December 31, 2005 | 6.07M |
| December 31, 2004 | 4.744M |
| December 31, 2003 | 5.21M |
| December 31, 2002 | 4.471M |
| December 31, 2001 | 2.780M |
| December 31, 2000 | 2.681M |
| December 31, 1999 | 2.448M |
| December 31, 1998 | 2.60M |
| December 31, 1997 | 1.80M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
4.138M
Minimum
2022
5.325M
Maximum
2019
4.684M
Average
4.497M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Amarin Corp PLC | 22.22M |
| DBV Technologies SA | 60.22M |
| Ascendis Pharma AS | 447.61M |
| Cellectis SA | 87.65M |
| Adaptimmune Therapeutics PLC | 126.51M |